FDA accepts Unicycive kidney-drug application and sets March 2027 review deadline
On October 21, 2026, Unicycive Therapeutics reported that FDA reviewers had allowed its renewed application for oxylanthanum carbonate to enter review. The agency classified the filing as Class II and set March 25, 2027, as its target decision date. The submission adds Chemistry, Manufacturing, and Controls information from a new third-party drug-product supplier after a June 2026 Complete Response Letter cited deficiencies at the prior supplier. FDA did not identify concerns with the drug's clinical, preclinical or safety information.
Why it matters
The action moves oxylanthanum carbonate into another FDA review cycle but does not grant marketing approval. The timing of any inspection and the eventual regulatory decision remain unresolved.
Key facts
- 1FDA gave the resubmitted application a Class II designation with a six-month review period and a March 25, 2027, PDUFA target date. stocktitan.net
- 2The filing contains CMC information from a new third-party drug-product manufacturer whose facility received No Action Indicated status after an FDA inspection in March 2024. stocktitan.net
- 3The earlier Complete Response Letter was received in June 2026 and cited deficiencies at the original third-party drug-product manufacturer. stocktitan.net
- 4Unicycive is pursuing approval through the 505(b)(2) regulatory pathway. investing.com
- 5The FDA raised no concerns about the clinical or safety data in the original application. stocktitan.net
Open questions
- The company does not know whether FDA will conduct a pre-approval inspection of the new manufacturing vendor.
- The FDA's eventual decision on the application is not known.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.